Glycinebetaine

Glycinebetaine

SCHEMBL3920896

C[N+](C)(C)CC(=O)[O-].Cc1cc[n+](CCCCCC(=O)O)c2ccc(S(=O)(=O)[O-])cc12

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BHMTBHMT2

The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 2/20 0.40
MAPT P10636 3/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.31
MEN1 O00255 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6262227 0.92 KDM4E (0.49) KDM4EPOLBALDH1A1MAPTHSD17B10
Glycinebetaine SCHEMBL3919091 0.79 ALDH1A1 (0.33) ALDH1A1
SCHEMBL7069818 0.77 KDM4E (0.54) KDM4EPOLBALDH1A1MAPTHSD17B10
Glycinebetaine SCHEMBL3924615 0.76 ALDH1A1 (0.32) ALDH1A1MEN1KMT2A
Bromide SCHEMBL3916333 0.76 KDM4E (0.56) KDM4EPOLBALDH1A1MAPTHSD17B10
Glycinebetaine SCHEMBL3927513 0.74 MEN1 (0.34) KDM4EPOLBALDH1A1MAPTHSD17B10
Glycinebetaine SCHEMBL3919698 0.72 MEN1 (0.33) MAPTLMNAMEN1KMT2ARECQL
SCHEMBL1105809 0.72 KDM4E (0.77) KDM4EPOLBMAPTKMT2ASMN1; SMN2
Glycinebetaine SCHEMBL16817756 0.72 RCE1 (0.37) KDM4EPOLB
Bromide SCHEMBL3915979 0.71 KDM4E (0.80) KDM4EPOLBALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563907-B2 Compounds based on polymethines DYOMICS GMBH (DE) 2009-07-21 US disclosed
US-20040260093-A1 Compound, especially marker-dye on the basis of polymethines DYOMICS GMBH (DE) 2004-12-23 US disclosed
US-20030165942-A1 Compound, especially marker-dye, on the basis of polymethines DYOMICS GMBH (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030165942-A1 Compound, especially marker-dye, on the basis of polymethines MKI67, CYBA, IK KDM4E 2432/4885POLB 1040/4885ALDH1A1 951/4885
US-20040260093-A1 Compound, especially marker-dye on the basis of polymethines MKI67, IK, CYBA KDM4E 2399/4885POLB 838/4885ALDH1A1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.